Glenmark announced the discovery and initiation of studies of a novel clinical development candidate, GBR 1302, the company said in a state...

Glenmark Pharmaceuticals S.A., a wholly owned Swiss subsidiary of Glenmark Pharmaceuticals, said GBR 830 is entering human trials.

Glenmark Pharmaceuticals opened a new manufacturing facility in Switzerland for supply of clinical trial material.

GBR 900 is a monoclonal antibody for the treatment of chronic pain targeting TrkA, the receptor of nerve growth factor (NGF).

Glenmark Pharmaceuticals said its novel chemical entity for potential treatment of chronic inflammatory disorders is entering human trials.

Glenmark Pharmaceuticals initiates studies to develop a new molecule 'GBR 830', which could treat diseases like Arthritis (RA) and bowel di...

Glenmark Pharmaceuticals said it has entered the phase II clinical trials for its new drug molecule aimed at treating ulcerative colitis.

Glenmark has netted over $200 million in milestone and upfront payments while it has spent about $120-130 million on research.

Glenmark Pharmaceuticals has licensed a new biotech drug to France's Sanofi which has the potential to generate revenues of $613 million or...

The global pecking order of blockbusters may soon be heading for a major upheaval with biotech drugs toppling the present market leaders.